he obesity epidemic is a global public health concern that threatens to reduce life expectancy around the world. 1,2 Excess weight, particularly abdominal obesity, causes or exacerbates cardiovascular and metabolic risk factors, including hypertension, dyslipidemia, and type 2 diabetes mellitus (T2DM). [3] [4] [5] These risk factors synergistically increase the likelihood of morbidity and mortality of cardiovascular disease (CVD), 6,7 which leads to rising healthcare costs. 8 Actions promoting health check-ups for obesity-related conditions and prevention strategies have been proposed; 9 however, the theoretical background has not been fully coordinated, and, most importantly, the actions to reduce abdominal adiposity has not been fully validated in terms of global cardiovascular risk management. The contribution of abdominal obesity to global cardiometabolic risk will be reviewed and the potential, underlying mechanisms and management strategy will be also discussed.
structure and function are altered in MetS, and affected patients seem more likely to show LV diastolic dysfunction, independently of LV mass. 15 Thus, in those patients Veglobal, an index of global LV relaxation function, decreased progressively from the absent group (0 of MetS component), pre-MetS group (1-2 components), to MetS group (≥3 components), even after adjustment for LV mass. 15 In patients hospitalized for CHF, 30-40% present only with LV diastolic dysfunction, but not with LV systolic dysfunction. 16 The presence of MetS provides important risk information beyond that of established risk factors also for congestive heart failure (CHF). In a community-based sample of middle-aged men, BMI and/or MetS was a significant predictor of CHF, independent of established CHF risk factors (hypertension, T2DM, LV hypertrophy and smoking). 17 The possible mechanisms by which MetS leads to LV diastolic dysfunction are discussed later.
Cerebrovascular Disease
In the Atherosclerosis Risk in Communities (ARIC) study, which included 14,448 men and women, Ohira et al determined the contribution of risk factors on ischemic stroke subtypes. 18 In addition to the traditional risk factors such as hypertension, current smoking and T2DM, the waist-to-hip ratio was associated with increased risk for non-lacunar and cardioembolic stroke, but not with lacunar stroke. The population-attributable fraction for hypertension was approximately 35% for all ischemic stroke subtypes. The population-attributable fraction for each of T2DM, current smoking, and waist-to-hip ratio were respectively 26.3%, 22.0% and -5.6% for lacunar, 11.3%, 11.4%, and 9.7% for non-lacunar, and 16.4%, 20.7% and 2.9% for cardioembolic stroke. In the Japanese population of the Hisayama Study, the multivariate-adjusted incidence of non-ischemic and ischemic stroke appeared higher in subjects with MetS in both men (hazard ration (HR) 1.68, P= 0.06 and 2.54, P=0.02) and women (1.78, P=0.01 and 0.99, P=0.91), as compared with those without MetS. 19 
Sudden Death and Arrhythmia
In the Paris Prospective Study I, which investigated the mortality of 6,678 middle-aged men who were free of T2DM and CHD at baseline, sagittal abdominal diameter, substituted for waist circumference, and the presence of MetS were associated with an increase in <1 h sudden death (multivariate-adjusted HR, 2.26 and 2.02), as with non-sudden death from AMI (HR 1.69 and 1.60). 20 Sudden death could be related to arrhythmic events, including lethal ventricular fibrillation, because patients with MetS had significantly higher values of corrected QT interval and QT dispersion on ECG, which reflects myocardial refractoriness and electrical instability. 21 In the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) study, 22 obesity (BMI ≥30 kg/m 2 ) was a risk factor for sustained ventricular tachyarrhythmia in patients after myocardial infarction with severe LV dysfunction (LV ejection fraction <30%).
In an analysis of 592 Japanese hospitalized patients without obvious structural heart disease, 23 MetS was a significant risk factor for paroxysmal atrial fibrillation/flutter, independent of left atrial diameter (>44 mm) or age (>70 years) (OR 2.8, P<0.01). In a community-based cohort in Japan (>28,000 subjects), Watanabe et al demonstrated an apparent correlation between the presence of MetS and increased susceptibility to atrial fibrillation. 24 Among the MetS components, obesity (BMI ≥25; age-and sex-adjusted HR, 1.64), as well as elevated blood pressure (systolic pressure ≥130 mmHg and/or diastolic pressure ≥85 mmHg; HR 1.69), low high-density lipoprotein-cholesterol (HDL-C; HR 1.52), and high fasting plasma glucose (≥110 mg/dl; HR 1.44), showed an increased risk for atrial fibrillation. 24 The association between MetS and atrial fibrillation remained significant in subjects without treated hypertension or T2DM (HR 1.78). Obesity and MetS were also shown to be independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. 25 Whether the increased atrial fibrillation risk in MetS is because of the syndrome as a whole or simply the sum of the risks of its individual components is currently equivocal.
Peripheral Arterial Disease (PAD)
There are few studies examining the relationship between obesity and PAD and whether obesity is a risk factor for the development of PAD remains controversial. 26, 27 The discrepancy may be related to the higher prevalence of PAD in elderly males and in smokers; elderly males show a weaker relationship between obesity and CVD, and smokers tend to have lower BMI than non-smokers. 28 A recent prospective cohort study revealed a positive relationship between waist-to-hip ratio, not BMI, and PAD prevalence. 29 Mechanisms by which obesity may cause PAD (if any) could be different to those for CHD, as they do have different risk profiles (eg, cigarette smoking is more strongly associated with the development of PAD than CHD). 30 Studies should be done to clarify the effects of obesity on the onset of PAD, complications such as rupture of aortic aneurysm, and the severity of limb ischemia.
Venous Thromboembolism
Numerous studies have shown a clear relationship between obesity and the risk of idiopathic venous thromboembolism (deep vein thrombosis and pulmonary embolism), independent of other traditional risk factors. 31, 32 For instance, in a study from Sweden, men with a waist circumference ≥100 cm had a 4-fold higher risk of venous thromboembolism than with those with a waist <100 cm. 32 Obese patients have chronically raised intra-abdominal pressure and decreased blood velocity in the common femoral vein. Inactivity and poor gait, as well as other comorbidities, may collectively impair venous return from the lower limbs. Alternatively, obesity, in particular visceral obesity, may have a prothrombotic propensity via mechanisms including actions of adipocytokine, increased activity of the coagulation cascade and decreased activity of the fibrinolytic cascade, inflammation, oxidative stress, endothelial dysfunction, and disturbances in lipids and glucose homeostasis. 32 
Mechanistic Link Between Abdominal
Obesity and CVD
Adipocytokine (Adipokine) and Insulin Resistance
There is solid evidence supporting the notion that excess abdominal fat is predictive of insulin resistance and the presence of related metabolic abnormalities currently referred to as MetS. [33] [34] [35] Despite the fact that abdominal obesity is a highly prevalent feature of MetS, the mechanisms by which abdominal obesity is causally related to the MetS are not fully elucidated.
Studies of the measurement of abdominal adiposity (magnetic resonance imaging and computed tomography) have commonly reached the conclusion that the amount of vis-ceral adipose fat, not that of subcutaneous abdominal fat, is a quite dominant correlate of metabolic abnormalities observed in overweight/obese patients. [3] [4] [5] 33 Individuals matched for subcutaneous abdominal adiposity, but with either a low or a high accumulation of visceral adipose tissue, clearly differ in their insulin sensitivity. [33] [34] [35] When categorized by whole-body distribution of adiposity, insulin sensitivity is well explained by ectopic fat deposition in insulin-sensitive non-adipose tissue (Fig 1) . Obese subjects constantly deliver more lipids and dysregulated adipocytokine than normal lean subjects; visceral fat obesity can produce more pro-atherogenic adipocytokine, including free fatty acids (FFA), than subcutaneous fat obesity. This concept is supported by the fact that subjects with generalized lipodystrophy, who cannot store fat in abdominal adipose tissue, but can store it in non-adipose tissue, showing the most severe form of insulin resistance.
Adipose tissue is not only an energy storage tissue, but also a metabolically active organ secreting hormones, cytokines and growth factors, collectively called as adipocytokine (adipokine), that act in an autocrine, paracrine or endocrine Effects of whole-body fat distribution on insulin sensitivity [47] [48] [49] [50] (see also text). TG, triglyceride.
Fig 2.
Lipotoxicity as a mechanism of obesity-related type 2 diabetes mellitus and the metabolic syndrome. FFA, free fatty acids. (Fig 1) . 3, 36 It is believed that anti-atherosclerotic adipocytokine, such as leptin and adiponectin, and proatherosclerotic cytokines, such as interleukin (IL)-6 and tumor necrosis factor (TNF)-α, cooperatively regulate metabolic and cardiovascular homeostasis at local and remote sites ( Table 1) . [3] [4] [5] 36 Obesity and the atherosclerotic process at least partly share an inflammatory etiology, 37, 38 which hypothetically causes an imbalance in the interaction between nitric oxide (NO) and reactive oxygen species (ROS), resulting in a pro-atherogenic vascular bed. 39 The association of insulin resistance to LV geometry can be linked to cardiac performance. LV hypertrophic remodeling can be considerably accounted for by insulin resistance, a major underlying condition in MetS. 40 This notion is supported by the fact that glucose intolerance is no longer a significant predictor of LV diastolic function after adjustment for BMI and HOMA-IR, a marker of insulin resistance. If insulin resistance primarily involves in the development of nonischemic heart failure, it could be called "insulin-resistant cardiomyopathy". 41 Comorbidity of hypertension, glucose intolerance and dyslipidemia individually may cause cardiac dysfunction directly via impaired relaxation of the LV and/or via vascular failure (endothelial dysfunction). 42 The excess production of ROS may elicit tissue damage in the heart, as shown in experimentally-induced heart failure model. 43 ROS could be involved in the pathophysiology of human CHF. 44 Systemic oxidative stress is enhanced in obese animals and in humans with visceral obesity 45 or MetS. 46 ROS derived from visceral fat could affect LV geometry and LV function.
Ectopic Fat Deposition and Lipotoxicity
Obesity is associated with lipid accumulation not only in adipose tissue, but also in non-adipose tissues. 47 The latter is known as ectopic fat deposition and lipotoxicity, which is theorized to produce obesity comorbidities such as insulin resistance, T2DM and CVD (Fig 2) . This concept was first described in pancreatic β-cells (β-cell lipotoxicity), [48] [49] [50] and expanded to other tissues including the heart. 51, 52 As obesity develops, insulin secretion increases parallel to insulin resistance in order to maintain normal glucose homeostasis. Patients predisposed to diabetes, however, fail to compensate for greater insulin requirements, and develop T2DM. 47 This phenomenon might be explained by a scenario of β-cell lipotoxicity, which is evidenced from studies with the ZDF rat, which has a loss-of-function mutation in the leptin receptor (OBRb) and shares features of obesity-related T2DM. This animal model secretes excess insulin in response to FFA oversupply in the obese pre-diabetic phase, but chronically loses secretory capacity by gradual loss of β-cell mass via a FFA-dependent apoptotic pathway. 50 In diabetic patients, eventual impairment of insulin secretion is also related to pancreatic fat accumulation and FFA-induced loss of β-cells. 53 The remarkable hyperlipolytic activity of visceral adipose tissue, over the subcutaneous adipose tissue, contributes to exposure of the liver, skeletal muscle and even the cardiovascular system to excess FFA, which impairs insulin-dependent metabolic process, and leads to hyperinsulinemia, glucose intolerance (an increase in hepatic glucose production and decreases in skeletal and hepatic glucose uptake), hypertriglyceridemia (an increase in VLDL-apolipoprotein B secretion), low plasma HDL-C levels, and cardiovascular disturbance 47 (Fig 3) .
Cardiac Adiposity and Epicardial Fat (Cardiac Lipotoxicity)
Mechanisms by which abdominal adiposity causes dysfunctional cardiac performance remain unknown. 15, 17 From evidence presented here, my hypothesis is that ectopic fat deposition in the heart is causally related to cardiac performance and structural remodeling by the multiple components of (1) circulatory and locally-recruited fat, 54 (2) intra-and extra-myocellular fat, 51, 52 (3) perivascular fat, 55, 56 and (4) pericardial fat, 57, 58 collectively to be "cardiac lipotoxicity" (Fig 4) .
(1) Circulatory and Locally-Recruited Fat (Vascular Lipotoxicity) An oversupply of FFA into the bloodstream from visceral adipose tissue may disturb vascular homeostasis. In a model of obesity, a "vascular lipotoxicity" phenomenon by which FFA directly activates vascular ROS production and leads to endothelial dysfunction was found (Fig 5) . 54 Circulating FFA can acutely increase vascular ROS signals and chronically enhance vascular expression of the NADPH oxidase multisubunit complex, which is the major source of superoxide anion in the vasculature. 59, 60 Two general mechanisms underlying the activation of NADPH oxidase are an acute increase in oxidase complex formation secondary to post-translational modification of regulatory subunits or mitochondrial uncoupling, 61 and a chronic increase in the expression and abundance of component subunits. 59 A key mechanism of acute activation by FFA can be the protein kinase C-dependent phosphorylation of the p47phox regulatory subunit and its translocation to the Nox2/p22phox heterodimer to form fully assembled complexes. 54 Locally produced ROS 54 and fat-derived ROS 45 simultaneously react with NO, generate peroxynitrite and finally impair cGMPdependent vasodilatation. There is controversy about the effects of FFA on insulin-mediated eNOS activation and angiotensin type 1 receptor signaling.
(2) Intra-and Extra-Myocellular Fat Intra-and extramyocellular fat is shown to be closely related to visceral fat adioposity in animal models 51, 52 and in humans. 62 Fat accumulation in the myocardium is associated with LV hypertrophy and dysfunction that ultimately progresses to lipotoxic heart disease. 51 Myocardial fat accumulation and lipotoxic cardiomyopathy in the animal model model can be prevented by an insulin-sensitizer treatment initiated at an early age. 47 In humans, Szczepaniak et al 62 showed that the contractile function of myocardium measured by MRS was negatively correlated with myocardial triglyceride (TG) levels (Figs 4B, C), and they also found that elevated myocardial TG levels develop LV concentric hypertrophy (Fig 4C) . This observation suggests that high myocardial TG levels herald contractile dysfunction in humans.
(3) Perivascular Fat Perivascular fat is another candidate of mediator for obesity-associated cardiovascular risk. It is defined as the accumulation of fat around vascular structures, mostly in the proximity of all blood vessels and around the coronaries and aorta (Fig 4) . Conventionally, perivascular fat was considered to act largely as a structural support for vasculature, but recent experimental data from ex-vivo epicardial adipose tissue and arteries suggest that periadventitial fat can modulate vascular responsiveness to vasoactive agents. 55, 56 Perivascular fat can secrete a variety of cytokines and chemokines 56 and can contribute to the pathogenesis and/or progression of obesity-induced atherosclerosis.
(4) Pericardial Fat Accumulation of excess pericardial fat, which shares with visceral fat the capacity to secrete cytokines, 57,58 might be related to cardiac remodeling. 58 Its quantity correlates well with the mass of visceral adipose tissue. 57, 58 Human pericardial adipose tissue has considerable secretory activity; epicardial adipose tissue from patients undergoing elective coronary aortic bypass grafting contained more mRNA and protein for IL-1β, IL-6, monocyte chemoattractant protein 1 and TNF-α than subcutaneous adipose tissue. 63 In pericardial tissue, the cytokine concentrations correlate well with the accumulation of inflammatory cells, such as T-lymphocytes, macrophages and mast cells. Adiponectin might also play a role in pericardial adipose tissue, as patients with advanced CHD have lower levels of epicardial adiponectin. 64 A recent clinical study showed that pericardial adipose tissue represents a novel indicator of cardiovascular risk. 65 
Management Strategy for Global Cardiometabolic Risk

Individual Risk Factors
Traditional risk factors, such as hypertension, elevated low-density lipoprotein-cholesterol, smoking, and diabetes mellitus, have long been linked to CVD. Although remarkable progress has been made in the management of these classical risk factors, abdominal obesity/MetS and T2DM have reached such epidemic proportions that CVD remains a major cause of morbidity and mortality worldwide. As discussed already, abdominal obesity is the most prevalent form of the clustering of pro-atherogenic and pro-inflammatory abnormalities associated with insulin resistance. The extent to which the specific clustering of visceral obesity abnormalities increases the overall CVD risk remains to be elucidated.
The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), as well as the International Chair on Cardiometabolic Risk, have emphasized the critical importance of first using global risk calculators such as the Framingham risk score, the PROCAM algorithm or the European SCORE. 66, 67 However, there is evidence to suggest that the risk assessment algorithms may not accurately estimate the global CVD risk in patients with visceral obesity/MetS. 68 Thus, it is essential to develop a risk assessment model of global CVD in the presence of traditional risk factors and the emerging markers found in individuals with visceral obesity. Després et al defined this model as global cardiometabolic risk 69 . Under this model, cardiometabolic risk is the global risk of CVD resulting from the presence of traditional risk factors combined with the possible additional contribution of the MetS. Namely, MetS cannot be used to assess global CVD risk but is at best another modifiable CVD risk factor.
It is also claimed that the Framingham risk score does not properly assess lifetime risk, particularly among young adults or adolescents with abdominal obesity, 68 who are not considered at risk of CVD by current algorithms because of their youth. Surrogate markers to detect abnormalities in ROS and the renin -angiotensin -aldosterone system, vascular failure (endothelial dysfunction), 42 neurohumoral stress and arrhythmogenicity could have additional powers in long-term assessment of global CVD risk (Fig 6) .
Visceral Fat Management
Obesity management goals should encompass a reduction in total cardiovascular morbidity and mortality. Losing 5-10% of body weight reduces the traditional CV risks. 9, 70 Increasing physical activity, in combination with a diet that emphasizes fresh fruits and vegetables, whole grains, and low-fat dairy products, can help patients reduce their weight and obesity comorbidity.
Less is known about the long-term effect of weight loss on the development of T2DM and CVD outcomes in the form of death, myocardial infarction, and stroke. Currently ongoing are clinical trials that use health-promoting lifestyle interventions, new drugs and even surgery, which are all aimed at weight loss, reduction in disease manifestations, and improved outcomes. 71 A trial to answer the most important question whether the improvements in cardiovascular risk factors by managed weight loss will be associated with reduction in long-term cardiovascular events is under investigation (The Look AHEAD (Action for Health in Diabetes) trial), 71 and the expected data are essential for the future development of effective CVD prevention strategies.
Conclusion
The concept of the MetS takes into account the central role that visceral fat plays in the development of metabolic and CVDs, and indicates how waist circumference measurement is useful for patient identification in the clinical setting. The MetS cannot be used to assess global CVD risk, but is at best 1 more modifiable CVD risk factor. Thus, global cardiometabolic risk should be considered individually. Increased visceral fat is associated with a shift in the normal balance of adipocytokine, resulting in a pro-inflammatory and pro-atherosclerotic state. Although evidence for therapeutic efficacy in the treatment of abdominal adiposity and clustering of cardiometabolic risks are limited, this is a promising challenge to reduce the highly contagious state around the world. As better understanding of the underlying molecular mechanisms develops, potential therapeutic targets will be identified.
